Sunday 18 October 2026
Export XAIR’s income statement to Excel — free account
Beyond Air, Inc.
XAIR Healthcare Medical Devices
Beyond Air, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $7.7 million, up 107.3% from fiscal 2025. In the quarter to June 2026, revenue was flat, EPS grew 64.1%, free cash flow fell 9.10% and total debt rose 127.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
2.16
0.05
−2.26%
Follow XAIR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.84 | 0.75 | 0.90 | 2.53 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.30) | (1.16) | (1.48) | (3.30) | |
P/B ratio |
2.27 | 0.92 | 0.76 | 1.12 | |
Price to Tangible BV |
3.44 | 1.10 | 0.87 | 1.23 | |
EV/Sales |
1.77 | 1.37 | 1.53 | 2.44 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.73) | (0.58) | (0.53) | (0.60) | |
EV/FCF |
(0.69) | (0.55) | (0.48) | (0.54) | |
Quick Ratio |
2.37 | 2.82 | 3.81 | 2.68 | |
Current Ratio |
3.31 | 3.80 | 5.12 | 4.24 | |
Net Debt/EBITDA |
(1.35) | (0.78) | (0.74) | 0.12 | |
Debt/Assets |
68.10% | 62.29% | 59.75% | 32.57% | |
Debt/Equity |
7.89 | 3.55 | 2.65 | 0.77 | |
Asset Turnover |
0.25 | 0.23 | 0.20 | 0.14 | |
Operating CF/Net income |
0.62 | 0.48 | 0.58 | 0.56 | |
Capex/Depreciation |
(0.16) | (0.51) | (0.03) | (0.26) | |
Interest Coverage |
(4.43) | (5.78) | (6.06) | (11.99) | |
Research and Development Expense of Revenue |
110.80% | 119.35% | 110.71% | 134.76% | |
Selling, General and Administrative Expense of Revenue |
275.90% | 261.56% | 203.60% | 270.24% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.04 | |
Share Based Compensation of Revenue |
58.60% | 22.39% | 68.51% | 97.63% | |
Graham Net Nets |
(1.12) | (0.77) | (0.47) | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(766.82%) | (637.68%) | (747.93%) | (328.14%) | |
Free Cash Flow Yield |
(304.62%) | (334.63%) | (353.72%) | (178.04%) | |
Revenue per Share |
2.45 | 4.59 | 5.09 | 5.72 | |
Operating CF per Share |
(6.86) | (11.92) | (9.79) | (14.01) | |
Capex per Share |
(0.29) | (1.32) | (0.08) | (0.77) | |
Free Cash Flow per Share |
(7.15) | (13.23) | (9.87) | (14.78) | |
Cash per Share |
21.10 | 41.59 | 41.42 | 34.16 | |
Shareholders Equity per Share |
3.94 | 14.96 | 19.23 | 41.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.94 | 14.96 | 19.23 | 41.19 | |
Free Cash Flow |
(5.15) | (5.49) | (4.25) | (4.70) | |
Working Capital |
15.94 | 18.26 | 20.58 | 14.20 | |
Capital Expenditures |
(0.21) | (0.55) | (0.03) | (0.25) | |
Net Current Asset Value |
(7.20) | (4.41) | (2.92) | 0.72 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.12 | 0.29 | 0.02 | 0.14 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.97 | 0.90 | 0.90 | 0.72 | |
Average Payables |
1.85 | 2.18 | 2.28 | 1.70 | |
Average Inventory |
1.86 | 1.91 | 2.07 | 2.38 | |
Average Assets |
30.50 | 32.72 | 35.46 | 41.99 | |
Average Common Equity |
6.62 | 10.28 | 13.33 | 21.19 |
Columns are period end dates · fundamentals updated 28 Sep 2026